{"url_path":"/sec/oncy/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000045-index.html","accession_number":"0001129928-26-000045","cik":"0001129928","ticker":"ONCY","issuer_name":"ONCOLYTICS BIOTECH INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000045-index.html","primary_entity_key":"0001129928","primary_entity_name":"ONCOLYTICS BIOTECH INC"},"word_count":113,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn July 20, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing pelareorep in combination with a checkpoint inhibitor was granted Fast Track Designation from the U.S. Food and Drug Administration for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who progressed on or were intolerant to one or more prior lines of systemic therapy. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section."}